Lipocine (LPCN) Stock Price, News & Analysis

Company Overview

Lipocine Inc. is a clinical-stage pharmaceutical company specializing in the development and commercialization of oral drug-delivery technologies for endocrine and metabolic disorders. The company’s proprietary lipid-based delivery platforms are designed to enhance the absorption and bioavailability of lipophilic compounds, with an initial focus on testosterone replacement therapy. Through these innovative formulations, Lipocine aims to offer patient-friendly alternatives to injectable or transdermal treatments.

The company’s lead asset, TLANDO, is an FDA-approved oral testosterone product for the treatment of male hypogonadism. TLANDO is designed to be taken twice daily and provides a predictable pharmacokinetic profile without the need for dose titration. In addition to its commercial efforts for TLANDO, Lipocine is advancing a pipeline of oral prodrug candidates, including LPCN 1144 for non-alcoholic steatohepatitis (NASH) and LPCN 1148, a testosterone formulation aimed at addressing bone health in men with osteoporosis.

Founded in 2003 and headquartered in Salt Lake City, Utah, Lipocine completed its initial public offering in 2013 and has since established strategic collaborations to support its commercialization and development objectives. The company holds a broad portfolio of patents covering its lipid-based delivery systems, and it continues to explore new indications and partnerships to expand the reach of its oral therapies.

Lipocine’s leadership team brings together seasoned professionals from the pharmaceutical and biotechnology sectors. Chief Executive Officer Ilya Yuffa, who joined the company’s board in 2019 and assumed the CEO role in 2021, is supported by a management team with expertise in regulatory affairs, clinical development, and commercial strategy. As Lipocine advances its oral drug-delivery platforms, it remains committed to addressing unmet medical needs and improving patient adherence through innovative dosage forms.

Key Stats

• Today's Range: $3.15 to $3.37
• 50-Day Range: $2.87 to $3.99
• 52-Week Range: $2.68 to $7.61
• Volume: 29,978 shs
• Average Volume: 33,381 shs
• Market Capitalization: $17.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Lipocine Stock Analysis - MarketRank™

Lipocine scored higher than 58% of companies evaluated by MarketBeat, and ranked 562nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Lipocine has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Lipocine has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lipocine is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lipocine is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lipocine has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.17% of the float of Lipocine has been sold short.

Short Interest Ratio / Days to Cover

Lipocine has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lipocine has recently decreased by 6.94%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lipocine does not currently pay a dividend.

Dividend Growth

Lipocine does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.17% of the float of Lipocine has been sold short.

Short Interest Ratio / Days to Cover

Lipocine has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lipocine has recently decreased by 6.94%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Lipocine has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Lipocine this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for LPCN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lipocine insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.35% of the stock of Lipocine is held by insiders.

Percentage Held by Institutions

Only 9.11% of the stock of Lipocine is held by institutions.

LPCN Stock Analysis - Frequently Asked Questions

How have LPCN shares performed this year?

Lipocine's stock was trading at $4.88 at the start of the year. Since then, LPCN shares have decreased by 33.0% and is now trading at $3.27.

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) announced its quarterly earnings data on Thursday, May, 8th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.35). The specialty pharmaceutical company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.35 million.

When did Lipocine's stock split?

Shares of Lipocine reverse split on the morning of Friday, May 12th 2023.The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

How do I buy shares of Lipocine?

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lipocine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lipocine investors own include Zomedica (ZOM), Plug Power (PLUG), Workhorse Group (WKHS), Ovid Therapeutics (OVID), FuelCell Energy (FCEL), Fortress Biotech (FBIO) and KALA BIO (KALA).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LPCN
• CIK: 1535955
• Web: www.lipocine.com
• Phone: (801) 994-7383
• Fax: 801-994-7388
• Employees: 10
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Lipocine: $9.00
• High Price Target: $10.00
• Low Price Target: $8.00
• Potential Upside/Downside: +175.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $10 thousand
• Net Margins: N/A
• Pretax Margin: -146.12%
• Return on Equity: -26.68%
• Return on Assets: -24.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.64
• Quick Ratio: 15.64

Sales & Book Value

• Annual Sales: $11.20 million
• Price / Sales: 1.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.93 per share
• Price / Book: 0.83

Miscellaneous

• Outstanding Shares: 5,350,000
• Free Float: 5,010,000
• Market Cap: $17.49 million
• Optionable: No Data
• Beta: 1.30